141 related articles for article (PubMed ID: 15078987)
1. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures.
Banerjee NS; Rivera AA; Wang M; Chow LT; Broker TR; Curiel DT; Nettelbeck DM
Mol Cancer Ther; 2004 Apr; 3(4):437-49. PubMed ID: 15078987
[TBL] [Abstract][Full Text] [Related]
2. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
Nettelbeck DM; Rivera AA; Balagué C; Alemany R; Curiel DT
Cancer Res; 2002 Aug; 62(16):4663-70. PubMed ID: 12183423
[TBL] [Abstract][Full Text] [Related]
3. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.
Hernandez-Alcoceba R; Pihalja M; Qian D; Clarke MF
Hum Gene Ther; 2002 Sep; 13(14):1737-50. PubMed ID: 12396626
[TBL] [Abstract][Full Text] [Related]
4. Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.
Fontecedro AC; Lutschg V; Eichhoff O; Dummer R; Greber UF; Hemmi S
Virol J; 2010 Jul; 7():175. PubMed ID: 20670430
[TBL] [Abstract][Full Text] [Related]
5. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells.
Rivera AA; Davydova J; Schierer S; Wang M; Krasnykh V; Yamamoto M; Curiel DT; Nettelbeck DM
Gene Ther; 2004 Dec; 11(23):1694-702. PubMed ID: 15496964
[TBL] [Abstract][Full Text] [Related]
6. Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli.
Hoffmann D; Wildner O
BMC Biotechnol; 2006 Aug; 6():36. PubMed ID: 16887042
[TBL] [Abstract][Full Text] [Related]
7. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma.
Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
Hum Gene Ther; 2004 Jul; 15(7):637-47. PubMed ID: 15242524
[TBL] [Abstract][Full Text] [Related]
8. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
[TBL] [Abstract][Full Text] [Related]
10. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy.
Doronin K; Kuppuswamy M; Toth K; Tollefson AE; Krajcsi P; Krougliak V; Wold WS
J Virol; 2001 Apr; 75(7):3314-24. PubMed ID: 11238857
[TBL] [Abstract][Full Text] [Related]
11. Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer.
Chai D; Qiu D; Zhang Z; Yuchen Shi S; Wang G; Fang L; Li H; Li H; Tian H; Zheng J
J Cell Mol Med; 2020 Sep; 24(18):10744-10755. PubMed ID: 32725966
[TBL] [Abstract][Full Text] [Related]
12. New tools for the construction of replication-competent adenoviral vectors with altered E1A regulation.
Avvakumov N; Mymryk JS
J Virol Methods; 2002 May; 103(1):41-9. PubMed ID: 11906731
[TBL] [Abstract][Full Text] [Related]
13. Engineering regulatory elements for conditionally-replicative adeno-viruses.
Haviv YS; Curiel DT
Curr Gene Ther; 2003 Aug; 3(4):357-85. PubMed ID: 12871022
[TBL] [Abstract][Full Text] [Related]
14. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.
Hoffmann D; Meyer B; Wildner O
J Gene Med; 2007 Sep; 9(9):764-78. PubMed ID: 17640083
[TBL] [Abstract][Full Text] [Related]
15. The E4-6/7 protein functionally compensates for the loss of E1A expression in adenovirus infection.
O'Connor RJ; Hearing P
J Virol; 2000 Jul; 74(13):5819-24. PubMed ID: 10846061
[TBL] [Abstract][Full Text] [Related]
16. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor.
Takahashi M; Sato T; Sagawa T; Lu Y; Sato Y; Iyama S; Yamada Y; Fukaura J; Takahashi S; Miyanishi K; Yamashita T; Sasaki K; Kogawa K; Hamada H; Kato J; Niitsu Y
Mol Ther; 2002 May; 5(5 Pt 1):627-34. PubMed ID: 11991754
[TBL] [Abstract][Full Text] [Related]
17. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
[TBL] [Abstract][Full Text] [Related]
18. Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b.
Hedjran F; Shantanu K; Tony R
Cancer Gene Ther; 2011 Oct; 18(10):717-23. PubMed ID: 21818136
[TBL] [Abstract][Full Text] [Related]
19. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
Bilsland AE; Merron A; Vassaux G; Keith WN
Cancer Res; 2007 Feb; 67(3):1299-307. PubMed ID: 17283167
[TBL] [Abstract][Full Text] [Related]
20. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses.
Jiang H; Alemany R; Gomez-Manzano C; Medrano DR; Lemoine MG; Olson MV; Alonso MM; Lee OH; Conrad CC; Yung WK; Fueyo J
Neoplasia; 2005 Aug; 7(8):723-9. PubMed ID: 16207474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
